Author Index for Volume 29

Note: Page numbers preceded by S indicate May/June supplement.

A
Ahlin C, 253
Alexander M, 7, 57, 127, 183, 197, 245
Arvanitis D, 101

B
Becker SC, 20
Belcher D, 63
Berreth M, 195
Bliss JP, 214
Boissonneault N, 158
Brundin S, 253

C
Cypher S, 318
Czaplewski LM, 204

D
de Burgoa LJ, 74
Doellman D, 28
Duff K, S5

F
Farraj R, 101
Frey AM, 34
Fugate JH, 147

G
Gallant P, 338

H
Hadaway L, 137
Hamelin L, 81
Hamilton C, 74
Hankins J, 260
Hellström B, 253
Hicks RW, 20
Huebsch LB, 81

J
Jacobs BR, 28
Johansson E, 253

K
Kirmse J, S15
Klang-Söderkvist B, 253
Knue M, 28
Kobrynski LJ, 206
Koski CL, S21

L
LaGrange CA, 158
Lamondy AM, 89
Leff L, 326

M
McDiarmid S, 81

N
Nash P, 346
Nowobilski-Vasilios A, 151

P
Papavassiliou V, 101
Patterson JV, S21
Petterson K, 253
Phillips S, 266
Poole SK, 151

R
Reid B, 158

S
Scarlet C, 39
Scerbo MW, 214
Schears GJ, 34, 225
Schmidt EA, 214
Schultz AA, 338
Seidner D, 74
Sejismundo LP, 272
Smith B, 14
Stafford J, 74
Steiger E, 74
Stowell CP, S29

T
Trotochaud K, 165

V
Van Allen, D, 158
Viale PH, 283
Vizcarra C, 63

W
Walker SR, 101
Walsh M, 192

Author Index for Volume 29

Note: Page numbers preceded by S indicate May/June supplement.

A
Ahlin C, 253
Alexander M, 7, 57, 127, 183, 197, 245
Arvanitis D, 101

B
Becker SC, 20
Belcher D, 63
Berreth M, 195
Bliss JP, 214
Boissonneault N, 158
Brundin S, 253

C
Cypher S, 318
Czaplewski LM, 204

D
de Burgoa LJ, 74
Doellman D, 28
Duff K, S5

F
Farraj R, 101
Frey AM, 34
Fugate JH, 147

G
Gallant P, 338

H
Hadaway L, 137
Hamelin L, 81
Hamilton C, 74
Hankins J, 260
Hellström B, 253
Hicks RW, 20
Huebsch LB, 81

J
Jacobs BR, 28
Johansson E, 253

K
Kirmse J, S15
Klang-Söderkvist B, 253
Knue M, 28
Kobrynski LJ, 206
Koski CL, S21

L
LaGrange CA, 158
Lamondy AM, 89
Leff L, 326

M
McDiarmid S, 81

N
Nash P, 346
Nowobilski-Vasilios A, 151

P
Papavassiliou V, 101
Patterson JV, S21
Petterson K, 253
Phillips S, 266
Poole SK, 151

R
Reid B, 158

S
Scarlet C, 39
Scerbo MW, 214
Schears GJ, 34, 225
Schmidt EA, 214
Schultz AA, 338
Seidner D, 74
Sejismundo LP, 272
Smith B, 14
Stafford J, 74
Steiger E, 74
Stowell CP, S29

T
Trotochaud K, 165

V
Van Allen, D, 158
Viale PH, 283
Vizcarra C, 63

W
Walker SR, 101
Walsh M, 192

Subject Index for Volume 29

Note: Page numbers preceded by SJ indicate the January/February supplement (INS *Standards of Practice*), and those preceded by SM indicate the May/June supplement.

A

Abatacept, for rheumatoid arthritis, 326
Adalimumab, for rheumatoid arthritis, 326
Adhesive tape, vs. securement devices, 34, 225
Albumin, in fluid and electrolyte balance, 260
Anakinra, for rheumatoid arthritis, 326
Anaphylaxis, 39
Antiarrhythmics, for cardiac emergencies, 147
Anticytokines, for rheumatoid arthritis, 326
Antiemetics
  in chemotherapy, 283
  in pregnancy, 89
Argatroban, for heparin-induced thrombocytopenia, 318
Arrhythmias, pharmacologic management of, 147
Arthritis, rheumatoid, emerging new therapies for, 326
Asystole, pharmacologic management of, 147
Australia, peripheral intravenous catheter management practices in, 101
Autologous stem cell transplantation, Hickman vs. peripherally inserted central catheter for, 81

B

Biologic infusion therapy
  for rheumatoid arthritis, 326
  for vasculitis, 272
  monoclonal antibodies in, SM39
  parenteral, 63
Bradycardia, pharmacologic management of, 147

C

Canada, protocol recommendations for IV immunoglobulin administration in, 158
Cancer, chemotherapy for, nausea and vomiting in, 283
Cardiac emergencies, pharmacologic management of, 147
Catheter(s)
  central venous
    peripherally inserted, vs. Hickman catheter, for autologous stem cell transplant, 81
    written protocol for, 253
  flushing techniques for, 137
  peripheral intravenous
    discontinuation of, Visual Infusion Phlebitis scale for, 338
    dwell times for, 14
    management practices for, in Greek, Jordanian, and Australian teaching hospitals, 101
  peripherally inserted central
    in children, 28
    securement devices for, 34, 225
    vs. Hickman catheter, for autologous stem cell transplant, 81
  securement devices for, 34, 225
  umbilical, placement and complication management for, 346
CathSim system, for phlebotomy training, 214
Central venous catheters. *See also* Catheter(s)
  peripherally inserted
    for autologous stem cell transplant, 81
    in children, 28
    securement devices for, 34, 225
    vs. Hickman catheter, for autologous stem cell transplant, 81
  written protocol for, 253
Chemotherapy, nausea and vomiting in, 283
Children
  combined immune deficiencies in, 206
  peripherally inserted central catheters for, 28
Chronic inflammatory neuropathies, IV immunoglobulin for, SM21
Colony-stimulating factors, 147
Combined immune deficiencies, in children, 206
Continuing education, 293, SM45
CRNI Recertification, review questions for, 293, SM45

D

Darbopoietin alpha, 147
Defibrillation, 147
Dermatomyositis, IV immunoglobulin for, SM21
DiGeorge syndrome, 206
Disease-modifying antirheumatic drugs, for rheumatoid arthritis, 326
Drug abuse, ethical aspects of, 266

E

Editorials, 7, 57, 127, 183, 245, 309
Education and training
  continuing education review questions for, 293, SM45
  phlebotomy, virtual reality simulator vs. simulated limbs for, 214
  written protocol for central venous catheters in, 253
Electrocardiogram, in cardiac emergencies, 147
Enteral nutrition, for hyperemesis gravidarum, 89
Erythropoietin alpha, 147
Etanercept, for rheumatoid arthritis, 326

Ethical issues
in access to healthcare, 165
in substance abuse, 266

F
Fixation devices, 34, 225
Fluid and electrolyte balance, albumin in, 260
Flushing techniques, 137

G
Granulocyte colony-stimulating factors, 147
Granulocyte-macrophage colony-stimulating factors, 147
Greece, peripheral intravenous catheter management practices in, 101

H
Healthcare access, ethical aspects of, 165
Heart disease, emergency pharmacologic management in, 147
Heparin-induced thrombocytopenia, argatroban for, 318
Hickman catheter, vs. peripherally inserted central catheter, for autologous stem cell transplant, 81
Home parenteral nutrition, complications of, 74
Hyperemesis gravidarum, 89

I
IgM monoclonal gammopathy, IV immunoglobulin for, SM21
Immune deficiencies, in children, 206
Inclusion body myositis, IV immunoglobulin for, SM21
Inflammatory neuropathies, IV immunoglobulin for, SM21
Infliximab
for rheumatoid arthritis, 326
for vasculitis, 272
Infusion Nurses Society Annual Meeting
2005 Financial Report, 195
Chief Executive Officer's Report, 197
Presidential Address, 204
State of the Society Report for, 192
Infusion nursing standards of practice. *See* Standards of practice
Interleukin inhibitors, for rheumatoid arthritis, 326
Intravenous immunoglobulin
administration of, SM5
Canadian protocol recommendations for, 158
subcutaneous, SM15
for neurologic diseases, SM21

J
Jordan, peripheral intravenous catheter management practices in, 101

L
Lambert Eaton myasthenic syndrome, IV immunoglobulin for, SM21
Lewis Sumner syndrome, IV immunoglobulin for, SM21

M
Medication error reporting program, 20
MEDMARX program, 20
Monoclonal antibodies, SM39
for rheumatoid arthritis, 326
for vasculitis, 272
parenteral administration of, 63
Multifocal motor neuropathy, IV immunoglobulin for, SM21
Myasthenia gravis, IV immunoglobulin for, SM21
Myositis, inclusion body, IV immunoglobulin for, SM21

N
Nausea and vomiting
in chemotherapy, 283
severe, in pregnancy, 89
Needleless injection systems, flushing of, 137
New products and services, 45, 110, 172, 232, 297, 354
Noncompliance, ethical aspects of, 266
Nursing education. *See* Education and training
Nutrition, home parenteral, complications of, 74

P
Parenteral biologic therapy, 63
Parenteral nutrition
for hyperemesis gravidarum, 89
in home care, complications of, 74
Peripheral intravenous catheters. *See also* Catheter(s)
discontinuation of, Visual Infusion Phlebitis scale for, 338
dwell times for, 14
management practices for, in Greek, Jordanian, and Australian teaching hospitals, 101
Peripheral-short catheters. *See also* Catheter(s)
securement devices for, 34, 225
Peripherally inserted central catheters. *See also* Catheter(s)
in children, 28
securement devices for, 34, 225
vs. Hickman catheters, for autologous stem cell transplant, 81
Phlebitic peripheral intravenous catheter, removal of, Visual Infusion Phlebitis scale for, 338
Phlebotomy training, virtual reality simulator vs. simulated limbs for, 214
Polymyositis, IV immunoglobulin for, SM21
Pregnancy, hyperemesis in, 89
Pulseless electrical activity, pharmacologic management of, 147
Pumps, flushing, 137

R
Reporting, of medication errors, MEDMARX program for, 20
Rheumatoid arthritis, emerging new therapies for, 326
Rituximab. *See also* Monoclonal antibodies
for rheumatoid arthritis, 326
for vasculitis, 272

S
Securement devices, 34, 225
Severe combined immunodeficiency, 206
Simulated limbs, vs. virtual reality simulator, for phlebotomy training, 214
Standards of practice
for access devices, SJ45
for documentation, SJ18
for infection control and safety compliance, SJ25
for infusion equipment, SJ25
for infusion therapies, SJ58
for infusion-related complications, SJ58
for nonvascular access devices, SJ58
for nursing interventions, SJ58
for nursing practice, SJ12
for patient care, SJ18
for site care and maintenance, SJ48
for site selection and device placement, SJ37
State of the Society Report, 192
StatLock securement device, 34, 225
Stem cell transplantation, Hickman vs. peripherally inserted central catheter for, 81
Substance abuse, ethical aspects of, 266
Suture securement, vs. securement devices, 34
Syringes, for flushing, 137

T
Tape, vs. securement devices, 34, 225
Thrombocytopenia, heparin-induced, argatroban for, 318
Tocilizumab, for rheumatoid arthritis, 326
Total parenteral nutrition
for hyperemesis gravidarum, 89
in home care, complications of, 74
Training. *See* Education and training
Transplantation, stem cell, Hickman vs. peripherally inserted central catheter for, 81
Tumor necrosis factor-α inhibitors, for rheumatoid arthritis, 326

U
Umbilical catheters. *See also* Catheter(s)
placement and complication management for, 346

V
Vascular access devices, flushing techniques for, 137
Vasculitis, biologic infusion therapies for, 272
Ventricular fibrillation, pharmacologic management of, 147
Virtual reality simulator, vs. simulated limbs, for phlebotomy training, 214
Visual Infusion Phlebitis scale, for discontinuation of peripheral IV catheters, 338
Vomiting
in chemotherapy, 283
severe, in pregnancy, 89

W
Wiskott-Aldrich syndrome, 206

STATEMENT OF OWNERSHIP, MANAGEMENT, AND CIRCULATION (Act of August 12, 1970; Section 3685; Title 39 United States Code) Date of Filing—October 1, 2006. Title of Publication—*Journal of Infusion Nursing*; Frequency of Issue—Bimonthly; Annual Subscription Price—$101.95; Location of Known Office of Publication—Lippincott Williams & Wilkins, Inc., 16522 Hunters Green Parkway, Hagerstown, MD 21740-2116; Location of the Headquarters or General Business Offices of the Publisher—Lippincott Williams & Wilkins, Inc., 530 Walnut Street, Philadelphia, PA 19106; Publisher—Lippincott Williams & Wilkins, Inc., 530 Walnut Street, Philadelphia, PA 19106; Editor—Mary Alexander, Infusion Nurses Society, 220 Norwood Park South, Norwood, MA 02062. Managing Editor—Randi Davis, Lippincott Williams & Wilkins, Inc., 530 Walnut Street, Philadelphia, PA 19106; Owner—Infusion Nurses Society, 315 Norwood Park South, Norwood, MA 02062; Known Bond Holders, Mortgagees, and other security holders owning or holding 1 percent or more of the total amount of bonds, mortgages, or other securities—None. A. Total no. of copies printed (net press run), average 7,266, actual 7,200. B. Paid and/or requested circulation 1. Paid/requested outside-county mail subscriptions stated on form 3541, average 6,175, actual 6,148; 2. Paid in-county subscriptions, none; 3. Sales through dealers and carriers, street vendors, counter sales, and other non-USPS paid distribution, average 266, actual 270; 4. Other classes mailed through the USPS, none. C. Total paid and/or requested circulation [sum of B (1), (2), (3), and (4)], average 6,441, actual 6,418. D. Free distribution by mail (samples, complimentary, and other free). Outside-county as stated on form 3541, average 255, actual 296; 2. In-county as stated on form 3541, none; 3. Other classes mailed through the USPS, none. E. Free distribution outside the mail (carriers or other means), average 4, actual 9. F. Total free distribution (sum of D and E), average 259, actual 305. G. Total distribution (sum of C and F), average 6,700, actual 6,723. H. Copies not distributed, average 566, actual 477. I. Total (sum of G and H), average 7,266, actual 7,200. Percent paid and/or requested circulation, average 96.13%, actual 95.46%. I certify that the statements made by me above are correct and complete. *Jeffrey Brown, Manager, Periodicals Operations.*